Repertoire Immune Medicines

Executive Summary

Repertoire Immune Medicines is a clinical-stage biotechnology company focused on harnessing the immune system to combat cancer, autoimmune diseases, and infectious diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company leverages its proprietary platform to decode and reprogram immune responses. By targeting T cell receptors and antigens, Repertoire aims to develop personalized and off-the-shelf therapies that address unmet medical needs. The company's approach combines deep immune profiling with rational design to create therapies that can precisely modulate immune activity. Repertoire is privately held and has not yet disclosed its total funding or valuation, but it has advanced multiple programs into clinical development. In 2025, Repertoire continues to progress its pipeline toward key milestones. The company is expected to report initial clinical data from its lead programs in oncology and autoimmune indications. With a strong scientific foundation and a clear focus on translating immune insights into therapeutics, Repertoire is well-positioned to deliver meaningful results. Upcoming catalysts include data readouts from ongoing Phase 1/2 trials, potential strategic partnerships to expand its platform capabilities, and a likely Series C financing round to fund its expanding pipeline. These events could significantly de-risk the company's technology and validate its platform approach, enhancing its visibility and credibility in the competitive biotech landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical data readout in oncology40% success
• Q4 2026Strategic partnership for platform technology50% success
• Q2 2026Series C financing round70% success